British HIV Association(BHIVA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003)

HIV Medicine

Volumn 5, Issue SUPPL. 2, 2004, Pages 46-60

  Poppa, Anna ^a   Davidson, O ^a   Deutsch, J ^b   Godfrey, D ^b   Fisher, M ^c   Head, S ^d   Horne, R ^e   Sherr, L ^a  

^a Camden NHS Primary Care Trust ^*  (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BRIGHTON   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; CHILD CARE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DEMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; DRUG USE; EVIDENCE BASED MEDICINE; FATIGUE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; LIFESTYLE; MEDICAL AUDIT; MEDICAL LITERATURE; MEDICAL RECORD; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; OBSTETRICS; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT; SELF REPORT; SEXUAL BEHAVIOR; SOCIAL SUPPORT; SOCIOECONOMICS; STAFF TRAINING; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM; VIRUS IMMUNITY; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; SOCIAL SUPPORT;

EID: 4043059296     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00215.x     Document Type: Review

References (94)

1. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Molla A, Korneyeva M, Gao Q. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760-766.
3. Perelson AS, Neumann AU, Markowitz M. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
4. Kuritzkes DR, Quinn JB, Benoit SL. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-981.
5. Richman DD, Havlir D, Corbeil J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68: 1660-1666.
6. Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
7. Fischl M, Rodriguez A, Scerpella E. Impact of directly observed therapy on outcomes in HIV clinical trials. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2000, [Abstract 71].
8. Mannheimer S, Friedland G, Marts J. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34: 1115-1121.
9. Anderson W, Weatherburn P. Taking Heart? The Impact of Combination Therapy on the Lives of People with HIV (Phase 2). London, Sigma Research, 1999.
10. Marinker M. From Compliance to Concordance: Achieving Shared Goals in Medicine Taking. London, Royal Pharmaceutical Society of Great Britain and Merck Sharp and Dohme, 1997.
11. Sherr L. Understanding adherence. J HIV Ther 2000; 5: 30-35.
12. Vanhove GF, Schapiro JM, Winters MA. Patient compliance and drug failure in protease inhibitor monotherapy. J Am Med Assoc 1996; 276: 1955-1956.
13. Maher K, Klimas N, Fletcher MA. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. J Acquir Immune Defic Syndr 1999; 22: 358-363.
14. Hogg R, Yip B, Chan K. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. 13th International AIDS Conference. Durban, July 2000 [Abstract TuOrB419].
15. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the UK. Br Med J 2001; 322: 1087-1088.
16. Little SJ, Routy JP, Daar ES. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 756].
17. Little SJ, Holte S, Routy JP. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
18. BHIVA Writing Committee BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
19. Cohen V, Maggio C, Triplett JW. Relationship between antiretroviral prescription compliance and immunologic, virologic and clinical outcomes. Pharmacotherapy 1997; 17: 1091.
20. Stansell J, Barrett J, DeGuzman C. Incremental costs of HIV suppression in HIV therapeutic failure. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2000 [Abstract 761].
21. Bangsberg DR, Perry S, Charlesbois ED. Adherence to HAART predicts progression to AIDS. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 483].
22. Leake H, Horne R. Optimising adherence to combination therapy. J HIV Ther 1998; 3: 67-71.
23. Horne R. One to be taken as directed: reflections on non-adherence. J Social Admin Pharm 1993; 10: 150-156.
24. Yeni PG, Hammer SM, Carpenter CCJ. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2002; 288: 222-235.
25. Horne R. Adherence to medication: a review of existing research, In: Myers L, Midence K. eds. Adherence to Treatment in Medical Conditions. London, Harwood Academic 1998: 285-310.
26. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998; 129: 573-578.
27. Carrieri P, Cailleton V, le Moing V. The dynamic of adherence to Highly Active Antiretroviral Therapy: Results from the French National APROCO Cohort. J Acquir Immune Defic Syndr 2002; 28: 232-239.
28. Bamberger JD, Unick J, Kein P. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health 2000; 90: 699-701.
29. Singh N, Squier C, Sivek C. Determinants of compliance with antiretroviral therapy in patients with HIV: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 281.
30. Murphy DA, Wilson CM, Durako SJ. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001; 13: 27-40.
31. Eldred IJ, Wu AW, Chaisson RE. Adherence to antiretroviral and pneumocystic prophylaxis in HIV disease. J Acquir Immune Defic Syndr 1998; 18: 117.
32. Tuldra A, Fumaz CR, Ferrer MJ. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25: 221-228.
33. Horne R, Buick D, Fisher M. Perceptions of HIV and HAART as barriers to adherence. 5th AIDS Impact. Brighton, July 2001 [Abstract 105].
34. Walsh JC, Horne R, Dalton M. Reasons for non-adherence to antiretroviral therapy: patients' perspectives provide evidence of multiple causes. AIDS Care 2001; 13: 709-720.
35. Horne R, Weinman J. Self-regulation and self-management of asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health in press.
36. Horne R, Sumner S, Jubraj B. Haemodialysis patients' beliefs about treatment implications for adherence to medication and diet/fluid restrictions. Int J Pharmacy Prac 2001; 9: 169-175.
37. Peters KF, Horne R, Kong F. Living with Marfan Syndrome 2. Medication adherence and physical activity modification. Clin Genet 2001; 60: 283-292.
38. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosomatic Res 1999; 47: 555-567.
39. Horne R. Compliance, adherence and concordance, In: Taylor K, Harding G. eds. Pharmacy Practice. London, Taylor & Francis 2001: 165-184.
40. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002; 29 (Suppl. 1): S2-S10.
41. Duran S, Saves M, Spire B. Failure to maintain long-term adherence to highly active antiretroviral therapy. the role of lipodystrophy. AIDS 2001; 15: 2441-2444.
42. Cingolani A, Antinori A, Rizzo MG. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16: 369-379.
43. Kuritzkes DR. HIV-1 drug resistance and medication adherence in patients receiving nucleoside reverse transcriptase inhibitors (NRTI). Antiviral Ther 2001; 6 (Suppl. 1): 84.
44. Muma RD, Ross MW, Parcel G. Zidovudine adherence amongst individuals with HIV infection. AIDS Care 1995; 7: 439.
45. Burger DM. Therapeutic drug monitoring of nelfinavir 1250 mg bid improves therapeutic outcome after one year: results from ATHENA. 2nd International Workshop in Clinical Pharmacology of HIV Therapy. Noordwijk, April 2001 [Abstract 6.2b].
46. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl. 2): S171-S176.
47. McPherson-Baker S, Malow RM, Penedo F. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000; 12: 399-404.
48. Rehder TL, McCoy LK, Blackwell B. Improving medication compliance by counseling and special prescription container. Am J Hosp Pharm 1980; 37: 379-385.
49. Walsh JC, Sherr L. The Adherence Strategy Group. An assessment of current HIV treatment adherence services in the UK. AIDS Care 2002; 14: 329-334.
50. Alexander D, Johnson D, Mann P. The well patient visit: improving adherence/compliance through a nursing intervention. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [Abstract 700].
51. Haddad M, Inch C, Glazier RH. Patient Support and Education for Promoting Adherence to Highly Active Antiretroviral Therapy for HIV/AIDS (Cochrane Review). In the Cochrane Library 2001, 1. Oxford, Update Software, 2001.
52. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med 1963; 268: 1334-1338.
53. Gifford AL, Bormann JE, Shively MJ. Effects of group HIV patient education on adherence to antiretrovirals: a randomized controlled trial. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 479].
54. Rigsby MO, Rosen MI, Beauvais JE. Cue-dose training with monetary reinforcement: a pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000; 15: 841-847.
55. Wall TL, Sorensen JL, Batki SL. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995; 37: 261-269.
56. Altice FL, Mostashari F, Friedland GH. Trust and acceptance of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28: 47-58.
57. Webb DG, Horne R, Pinching AJ. Treatment-related empowerment: preliminary evaluation of a new measure in patients with advanced HIV disease. Int J STD AIDS 2001; 12: 103-107.
58. Parkin JM, Murphy M, Anderson J. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355: 722-723.
59. Benn PD, Mercey DE, Brink N. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357: 687-688.
60. Kahn JO, Martin JN, Roland ME. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis 2001; 183: 707-714.
61. Laine C, Newschaffer CJ, Zhang D. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol 2000; 95: 167-173.
62. Turner BJ, Newschaffer CJ, Zhang D. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care 2000; 38: 911-925.
63. Melvin D, Sherr L. The child in the family - responding to AIDS and HIV. AIDS Care 1993; 5: 35-42.
64. Pontali E, Feasi M, Toscanini F. Adherence to combination antiretroviral treatment in children. HIV Clin Trials 2001; 2: 466-473.
65. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
66. Cahn P. Potential advantages of a compact triple nucleoside regimen; efficacy and adherence with Combivir/abacavir versus Combivir/indinavir in an open-label randomised comparative study (CNAB3014). 40th ICAAC. Toronto, Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2000 [Abstract 695].
67. Bartlett JA, DeMasi R, Quinn J. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001; 15: 1369-1377.
68. Hedge B. Take as prescribed: a study of adherence behaviours in people taking antiretroviral medications. 12th World AIDS Conference. Geneva, July 1998 [Abstract 32348].
69. Stansell J, Holtzer C, Mayer S. Factors affecting treatment outcomes in a medication event monitoring system (MEMS) clinical trial of PI-containing HAART. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 478].
70. Tremblay C. HIV evolution during repeated supervised treatment interruptions following early antiretroviral treatment of acute infection. Antiviral Ther 2001; 6 (Suppl. 1): 17.
71. Fumaz CR, Tuldra A, Ferrer MJ. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002; 29: 244-253.
72. Leider J, Alpert P. Using simulated HIV therapy to assess adherence barriers to combination therapy. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [Abstract 706].
73. Liu H, Golin CE, Miller LG. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 968-977.
74. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16: 269-277.
75. Miller LG, Liu H, Hays RD. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002; 17: 1-11.
76. Bangsberg DR, Hecht FM, Clague H. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 435-442.
77. Marzolini C, Telenti A, Decosterd LA. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71-75.
78. Durant J, Clevenbergh P, Garraffo R. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS 2000; 14: 1333-1339.
79. Hugen PW, Langebeek N, Burger DM. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 2002; 30: 324-334.
80. van Rossum AM, Bergshoeff AS, Fraaij PL. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 743-747.
81. Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002; 15: 17-22.
82. Wendel CS, Mohler MJ, Kroesen K. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother 2001; 35: 1010-1015.
83. Parienti JJ, Verdon R, Bazin C. The pills identification test: a tool to assess adherence to antiretroviral therapy. J Am Med Assoc 2001; 285: 412.
84. Descamps D, Flandre P, Calvez V. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy Trilege. (Agence Nationale de Recherches sur la SIDA 072) Study Team. J Am Med Assoc 2000; 283: 205-211.
85. Havlir DV, Hellman NS, Petropoulos PJ. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. J Am Med Assoc 2000; 283: 229-234.
86. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999: 14-24.
87. Horne R, Buick D, Fisher M. Patients' beliefs about HAART influence adherence to antiretroviral therapy. 39th ICAAC. San Francisco, Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 1999 [Abstract 588].
88. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 1180.
89. Roter DL, Hall JA, Merisca R. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36: 1138-1161.
90. Knobel H, Carmona A, Lopez JL. [Adherence to very active antiretroviral treatment: impact of individualized assessment]. Enferm Infecc Microbiol Clin 1999; 17: 78-81 (in Spanish).
91. Goujard C, Peyramond D, Bernard N. Improved adherence to antiretroviral therapy at 6 months in HIV-1 infected individuals: impact of a face-to-face treatment education program: the Ciel Bleu study. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [Abstract 703].
92. Collier AC, Ribaudo H, Feinberg J. Randomized study of telephone calls to improve adherence to antiretroviral therapy. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [Abstract 540T].
93. Samet JH, Horton NJ, Dukes K. A randomised controlled trial of a multidimensional intervention to enhance adherence to antiretroviral therapy in HIV-infected patients with a history of alcohol problems. 14th International AIDS Conference. Barcelona, July 2002 [Abstract MoPeB3286].
94. Safren SA, Hendriksen ES, Boswell S. Twelve-week outcome of a cue-controlled paging system to increase ART adherence. 14th International AIDS Conference. Barcelona, July 2002 [Abstract WePeB5864].